Polycyclic Polyprenylated Xanthones from Symphonia globulifera: Isolation and Biomimetic Electrosynthesis
摘要:
Two regioisomeric polycydic xanthones, 3,16-oxyguttiferone A (2) and 1,16-oxyguttiferone A (3), which are polyprenylated acylphloroglucinol-derived analogues, were isolated from the seeds of Symphonia globulifera, together with their presumed o-dihydroxybenzoyl precursor, guttiferone A (1). Anodic oxidation of 1 into the corresponding o-quinone species proved to be an efficient biomimetic method to generate xanthones 2 and 3 in high overall yield and to confirm their structures. Both compounds displayed cytotoxicity against the HCT 116 colon carcinoma cell line with IC50 values of 8 and 3 mu M, respectively.
Synthesis of novel guttiferone A derivatives: In-vitro evaluation toward Plasmodium falciparum, Trypanosoma brucei and Leishmania donovani
作者:Yann Fromentin、Nicolas Gaboriaud-Kolar、Bruno Ndjakou Lenta、Jean Duplex Wansi、Didier Buisson、Elisabeth Mouray、Philippe Grellier、Philippe M. Loiseau、Marie-Christine Lallemand、Sylvie Michel
DOI:10.1016/j.ejmech.2013.04.066
日期:2013.7
The catechol pharmacomodulation of the natural product guttiferone A, isolated from the Symphonia globulifera tree, led to the semisynthesis of a collection of twenty derivatives. The ester and ether derivatives of guttiferone A were evaluated for their anti-plasmodial, trypanocidal and anti-leishmanial activities. Some compounds described below have shown potent antiparasitic activity against Plasmodium falciparum, Trypanosoma brucei and Leishmania donovani in a range from 1 to 5 mu M. The evaluation of guttiferone A derivatives against VERO cells highlighted catechol modulations as an interesting tool to decrease the toxicity and keep the activity of this natural compound. The current study revealed new molecules as promising new antiparasitic drug candidates. (C) 2013 Elsevier Masson SAS. All rights reserved.
METHODS OF TREATMENT USING SIRT MODULATORS AND COMPOSITIONS CONTAINING SIRT1 MODULATORS
申请人:Farmer Stephen R.
公开号:US20100210692A1
公开(公告)日:2010-08-19
Methods of treatment using SIR1 modulators and compositions containing SIRT1 modulators are described. Combinations of a SIRT1 modulator and a second agent, and uses of such combinations, are also described.
HISTONE DEACETYLASE INHIBITORS, COMBINATION THERAPIES AND METHODS OF USE
申请人:Baylin Stephen
公开号:US20110104177A1
公开(公告)日:2011-05-05
The invention relates to histone deacetylase (HDAC) inhibitors to treat proliferative diseases. The present invention provides novel class III histone deacetylase inhibitors, in particular SIRT1 inhibitors, to reverse the silencing of hypermethylated genes, in combination with one or more other agents, in proliferative diseases such as cancer. The present invention provides methods of activating genes that are silenced by methylation in a subject by administering a HDAC inhibitor in combination with one or more agents.